Sign in
Taking people in United StatesPhase 3

Metformin for leg pain when walking caused by blocked leg arteries

Tests metformin against placebo in veterans with intermittent claudication from peripheral arterial disease.

Key facts

Who runs it
VA Office of Research and Development
Where
Pittsburgh, United StatesSee the site
Trial code
Registry title
MetfOrmin BenefIts Lower Extremities With Intermittent Claudication
Status
Recruiting
Phase
Phase 3
People taking part
200 people, planned
Started
1 Mar 2022
Expected to end
28 Feb 2032
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Metformin ER
  • placebo
Record updated
21 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Veterans with peripheral arterial disease (narrowed leg arteries) who get leg pain when walking (intermittent claudication). It tests Metformin ER against a placebo.

Age
Older than 35 and younger than 89 (record lists 35 Years to 89 Years).
Sex
Men and women can join.
Disease stage
Leg pain with walking. PAD shown by ABI <0.9, or >0.9 with PAD seen on pulse volume recordings, within 6 months. On the 6-minute walk test, people must walk at least 50 meters, with pain starting at or before 400 meters, without a walker (a cane is allowed).
Earlier treatment
Standard medical care for more than 3 months before joining: statin and anti-platelet drugs, blood pressure control, smoking cessation and physical activity counseling. People cannot have taken metformin within 6 months of enrollment.
Biomarker or test result
Hemoglobin A1c must not be above 6.5. eGFR must not be below 45.

Main reasons for not taking part

  • Diabetes (Type I or II), or on dialysis
  • Other conditions that limit walking, such as angina, heart failure, lung disease needing oxygen, or cancer needing treatment
  • Prior above or below knee amputation, or severe limb ischemia (wounds that do not heal or pain at rest)
  • Major surgery or leg artery procedure in the past 3 months, or planned in the next 12 months
  • Pregnant or breastfeeding, liver failure, or cannot swallow whole pills

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Male and Female Veteran >35 \& <89
  • Symptoms of Intermittent claudication
  • Medically stable, optimal medical therapy (for >3 months prior to randomization which includes - statin and anti-platelet therapy, blood pressure control, smoking cessation and physical activity counseling); Participants may not comply with the above measures to meet inclusion criteria, but investigator driven attempts to maximize the optimal medical therapy, as tolerated, for each participant prior to trial enrollment
  • PAD as defined by ABI <0.9 or >0.9 with evidence of PAD as documented by pulse volume recordings (within 6 months prior to expected randomization date)
  • Maximum Walking Distance (MWD) on the 6-minute walk test (6MWT) of greater than or equal to 50 meters with onset of pain before or at 400 meters without the use of a walker (cane is acceptable; within 6 months of expected randomization date)

Who cannot take part

  • Currently Taking metformin or have previously taken metformin (within 6 months of enrollment)
  • Prior above or below knee amputation
  • Prior major operation or lower extremity revascularization (within the 3 months before expected randomization)
  • Medical condition that limit their ability to ambulate other than PAD (i.e., Angina, CHF, pulmonary disease requiring oxygen, malignancy requiring treatment, etc.)
  • Unable to complete quality of life testing due to Non-English Speaking and/or Dementia
  • Evidence current or history of hepatic failure
  • Diabetes (Type I or II) or Hemoglobin A1c>6.5 (within 6 months of expected randomization)
  • Kidney disease - dialysis or eGFR<45 (within 6 months of expected randomization date)*
  • Critical limb threatening ischemia (i.e., non-healing wounds or rest pain)
  • Planned hospital admission, major operation, or lower extremity revascularization to be completed (within 12 months after expected randomization date)
  • Planned iodinated contrasted study (within 6 months of expected randomization date)
  • Women who are pregnant or breast feeding
  • Unable to swallow uncrushed pills
  • Investigator expects inclusion could cause harm to subject

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 35 and 89 years old?

Where in United States

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PAPittsburgh, United StatesContact: Susan L BarrTaking people

About the trial

What the trial wants to find out

Peripheral arterial disease (PAD) affects over 20% of aged adults and is very common among Veterans due significant tobacco use. PAD is due to the progressive blockage of peripheral arteries, predominantly to the legs, and results in intermittent claudication (IC) or recurrent muscle pain with activity secondary to insufficient blood supply. Those with PAD and IC experience a progressive decline in walking and poor quality of life. There is no effective medical treatment for PAD and IC. Metformin is a safe and effective treatment for Type 2 diabetes but it can also reduce inflammation, oxidative stress, and improve energy requirements as well as improve blood flow to the legs. Therefore, the investigators will test the ability of Metformin to improve overall functional status, reduce PAD progression, and reduce systemic inflammation in Veterans suffering from PAD and IC in a randomized, placebo controlled trial: Metformin BenefIts Lower Extremities with Intermittent Claudication (MOBILE IC) Trial. The success of this trial may identify a safe and effective treatment for PAD and IC.

The 2 groups in the trial

  • Metformin ER 1000mgTreatment being tested

    daily by mouth

    Treatment: Metformin ER

  • Matching placeboPlacebo, for comparison

    daily by mouth

    Treatment: placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Metformin BenefIts Lower Extremities With Intermittent Claudication (MOBILE_IC)
Plain-language title
Metformin for leg pain when walking caused by blocked leg arteriesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05132439, who can take part
Publications
Record updated
21 April 2026